NPS Postpones Preos Filing To Add Two-Year Data From PaTH Study

NDA submission for the osteoporosis agent was originally slated for year-end 2004. Firm says two-year results have implications for use of Preos (recombinant parathyroid hormone) with Fosamax (alendronate).